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Należy cytować wersję pierwotną
Between 16 and 18 November 2019, Scientific Sessions, 
an event which the American Heart Association has 
organised for the last 94 years, was held in the city of 
Philadelphia. This international meeting attracted nearly 
15,000 participants interested in progress concerning 
pathomechanisms, diagnosis and treatment of heart and 
blood vessel diseases. It was, as always, an opportunity 
to summarise the breakthrough results of clinical trials. In 
2019, these included research programmes of particular 
significance which will undoubtedly influence clinical prac-
tice in the field of cardiology in the years to come.
The cardiologist (not only interventional) community 
was eagerly awaiting the announcement of results of 
the large-scale ISCHEMIA (International Study of Com-
parative Health Effectiveness With Medical and Invasive 
Approaches) trial, which was sponsored by the National 
Institute of Health and concerned the search for the 
most appropriate strategy with respect to patients with 
stable ischaemic heart disease and induced myocardial 
ischaemia proven in non-invasive tests. The trial included 
patients with moderate or severe ischaemia, defined via 
one of four methods: at least 10% stress-induced perfu-
sion loss in scintigraphy; or at least 12% in MRI, magnetic 
resonance imaging, test; or new myocardial contractility 
disorders observed during stress in at least 3/16 myocar-
dial segments assessed via echocardiography or MRI; or 
exercise electrocardiographic test. To meet the criteria 
for inclusion in the ISCHEMIA trial, it was required that 
ST segment depressions in exercise electrocardiographic 
test occur at fewer than seven metabolic equivalents 
(METs) or before peak heart rate was reached, below 75% 
of maximum heart rate, and be at least 1.5 mm deep in 
two adjacent leads or at least 2 mm deep in any lead, 
except for leads from above the prior myocardial infarction 
zone. It should be added that the presence of resting ST 
segment depressions of 1 mm or less, the presence of 
a left bundle branch block, the presence of left ventricular 
hypertrophy with repolarisation, or heart rhythm regula-
ted by a pacemaker constituted the exclusion criteria. 
The aim of the trial was to identify the most appropriate 
choice between two management options for this patient 
group: i.e. either optimal pharmacological therapy or 
pharmacotherapy preceded by coronary angiography and 
possible surgical or percutaneous revascularisation [1]. 
It should be noted that, given the contradictory results 
of smaller trials devoted to this issue, the ISCHEMIA trial 
was designed to be large-scale and ultimately included 
5,179 patients whose coronary artery anatomy was un-
known prior to randomisation, although 73% of the inclu-
ded patients underwent a CT scan of coronary arteries 
in order to exclude significant stenosis of the left main 
coronary artery, which was found in 8.7% of examined 
patients; 13.5% of patients from this group exhibited no 
significant coronary stenosis. 75% of the patients were 
recruited for this trial on the basis of a positive result of 
imaging stress tests (scintigraphy, echocardiography, and 
magnetic resonance imaging [MRI]; according to central 
analysis, the severity of ischaemia was overestimated in 
12% of patients), while the remaining 25% were included 
on the basis of a strongly positive exercise electrocardio-
graphy test. Five primary outcomes were defined: cardio-
vascular death, myocardial infarction, hospitalisation for 
unstable angina, hospitalisation for heart failure, and 
resuscitated cardiac arrest. Results were presented by 
Principal Investigator Judith Hochman from New York 
University; after five years of observation, the ISCHEMIA 
trial showed no significant differences in the number 
of events deemed primary outcomes: the percentage 
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primary outcomes not only for diabetic patients, but also 
— and this is the breakthrough — for non-diabetic heart 
failure patients. Comparison of effects of dapagliflozin 
and a placebo between diabetic and non-diabetic patients 
showed no significant differences in benefits stemming 
from administration of this drug: for instance, for the com-
pared groups, the odds ratio for cardiovascular death was, 
respectively, 0.79 and 0.85 at p = 0.7, while the quotient 
of probability of worsening of heart failure was 0.77 and 
0.67 at p = 0.23. Assessment of the quality of life change 
by at least 5 points, using the Kansas City Cardiomyopathy 
Questionnaire — Total Symptom Score (KCCQ-TSS) showed 
that for both diabetic and non-diabetic groups the percen-
tage of patients whose quality of life had improved was 
greater than the percentage of patients whose quality of life 
had deteriorated (p = 0.74). The safety profile of the tested 
drug was favourable, and adverse effects in the form of 
hypoglycaemia or metabolic acidosis were observed in only 
one promile of patients. The UK’s John McMurray, Principal 
Investigator for the DAPA-HF programme, stated during the 
congress that “this class of drugs, SGLT2 inhibitors, are 
more than just treatment for patients with diabetes. They’re 
potentially a lifesaving treatment that reduce heart failure 
hospital admission and improves symptoms in people with 
heart failure, irrespective of whether they’ve got diabetes 
or their HbA1c level”. Interestingly, none of the presented 
diabetes severity parameters affected the benefits of 
treatment using the SGLT2 inhibitor, and the strength of 
protection for non-diabetic patients was at least equal to 
results achieved by diabetic patients.
In terms of the size of the studied group of patients, 
the COLCOT (Colchicine Cardiovascular Outcomes Trial) 
programme was similar to DAPA-HF; the trial examined 
the extent to which colchicine — an anti-inflammatory drug 
known for many years and used in the treatment of gout 
and pericarditis — could reduce the number of ischaemic 
cardiovascular events in myocardial infarction survivors 
[3]. The trial included patients who had suffered a myo-
cardial infarction within the previous 30 days, randomly 
assigning them to a group which received 0.5 mg colchicine 
once daily or a placebo, in both cases as an addition to 
standard post-infarction treatment. Primary outcomes for 
the COLCOT trial were cardiovascular death, resuscitated 
sudden cardiac arrest, another myocardial infarction, 
stroke, or hospitalisation for unstable angina requiring 
revascularisation. After observation, which on average 
lasted 23 months, it was found that the group treated using 
colchicine exhibited a 23% reduction in the risk of a first 
vascular incident after a myocardial infarction and a 34% 
reduction in the risk of cumulative cardiovascular events 
in patients who recently suffered a myocardial infarction. 
The drug was well-tolerated by most patients, although 
a slight increase in the number of cases of pneumonia, 
and a statistically insignificant increase in gastrointestinal 
was 15% for the non-invasive group and 13.8% for the 
invasive group (p = 0.34). The trial revealed that for pa-
tients with symptomatic myocardial ischaemia confirmed 
in non-invasive tests, the strategy of utilising invasive 
coronary angiography to select management options 
(80% of patients underwent revascularisation of whom 
3/4 underwent percutaneous revascularisation) does not 
affect prognosis over a period of observation lasting an 
average of 3.3 years. This result is surprising, especially 
given the low percentage of complications stemming from 
revascularisation. The ISCHEMIA trial also unexpectedly 
indicated that the commonly used non-invasive methods 
for stratifying risk and guiding invasive management do 
not meet expectations, and it is difficult to find their place 
in prognostic reasoning. Moreover, the described results 
do not apply to patients with class III/IV New York Heart 
Association (NYHA) heart failure, with a left ventricular eje-
ction fraction of below 35% and an unacceptable level of 
angina, as well as with left main coronary artery stenosis 
or a recent (up to 60 days) history of acute coronary syn-
drome. Summarising the ISCHEMIA trial, Judith Hochman 
emphasised the relatively low mortality rate of patients 
treated in both trial groups and the ultimate conclusion 
stemming from the trial, i.e. the fact that, for the studied 
cohort, an invasive strategy did not lead to a lower risk 
of clinical events compared to a non-invasive strategy — 
the effect amounted to a stronger mitigation of angina in 
only three out of 100 treated patients. No criterion which 
would benefit either strategy was identified, including in 
a group of chronic kidney disease patients distinguished 
within the ISCHEMIA-CKD analysis.
The congress also provided interesting results con-
cerning the use of non-cardiac drugs in order to reduce 
cardiovascular risk — termed the ‘outside-the-box’ appro-
ach — meaning an unconventional application in the field 
of cardiology of drugs utilised for non-cardiac indications.
DAPA-HF (Study to Evaluate the Effect of Dapagliflozin 
on the Incidence of Worsening Heart Failure or Cardio-
vascular Death in Patients With Chronic Heart Failure) 
is a programme which has demonstrated that the drug 
dapagliflozin [a sodium-glucose cotransporter 2 (SGLT2) 
inhibitor] tested within the programme has similar bene-
fits in terms of reduction of cardiovascular risk for both 
diabetic and non-diabetic heart failure patients [2]; this 
latter observation was presented in Philadelphia in detail. 
The trial, the results of which were published in September 
2019, lasted 18 months and included 4,744 heart failure 
patients, of whom 45% were diabetic. Randomisation 
involved assignment to a group which received 10 mg 
dapagliflozin or to a group which received a placebo, irre-
spective of whether diabetes was diagnosed or not. Primary 
outcomes included death, hospitalisation for heart failure, 
or sudden events related to heart failure. Administration 
of dapagliflozin resulted in an approx. 26% reduction in 
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complications, were observed in the colchicine group. 
Jean-Claude Tardif from the Montreal Heart Institute Re-
search Centre, who served as the Principal Investigator 
for this non-sponsored programme, stated that through 
colchicine cardiologists have gained a drug that is “orally 
administered, availably in every country of the world and 
inexpensive”. Colchicine, with its recently identified me-
chanism of action through inflammasome inhibition, thus 
became an ‘unsung hero’ of the congress, one that will be 
hard to ignore in future editions of secondary prevention 
guidelines.
Presentation of results of therapies using innovative 
drugs was an important topic during the AHA session. One 
example of a completely new approach to hypolipidemic 
treatment is a drug called inclisiran — a short ribonucleic 
acid molecule interfering with messenger RNA, which 
blocks transcription of proprotein convertase subtilisin/ 
/kexin type 9 (PCSK-9) [4]; its unique feature is the fact 
that it need be administered only once every six months. 
The effects of inclisiran administration in patients with 
a stable course of atherosclerotic cardiovascular diseases 
and LDL (low-density lipoprotein) cholesterol concentra-
tion equal to or exceeding 70 mg/dL were tested in the 
ORION-10 (Inclisiran for Participants with Atherosclerotic 
Cardiovascular Disease and Elevated Low-density Lipo-
protein Cholesterol) programme. The outcomes in this 
programme were firstly the degree of LDL-cholesterol 
reduction compared to placebo at day 510 of treatment, 
and secondly the percentage reduction in LDL cholesterol 
concentration between days 90 and 540 of treatment. 
Injections with the studied drug/placebo were administered 
on day 1, then after 90 days, and then every six months. 
The ORION-10 trial, which included 1,561 patients rando-
mised 1:1 for active or placebo treatment, showed a 58% 
reduction in LDL-cholesterol concentration at day 510 of 
the trial, and a 56% reduction in this parameter between 
days 90 and 540 of the observation. The trial did not target 
clinical events, but their frequency was slightly lower in the 
group treated using inclisiran. Professor R. Scott Wright 
from the Mayo Clinic, who supervised this trial, stated that 
inclisiran is an “effective, long-lasting and strong” drug. 
Could it be that a serious competitor for recently introduced 
PCSK9 inhibitors has emerged?
Less spectacular, but no less noteworthy, were the 
results of the BETonMACE (Effect of RVX000222 on Time 
to Major Adverse Cardiovascular Events in High-Risk T2DM 
Subjects With CAD) trial, which studied whether apabetalo-
ne, a molecule created to block epigenetic transcription mo-
dulators (BET proteins) related to inflammatory processes, 
thrombogenesis and lipoprotein metabolism, would be able 
to reduce the number of vascular events in patients treated 
for acute coronary syndrome and diabetes [5]. 26 months 
of observation of 2,425 patients who underwent this in-
novative therapy failed to show a statistically significant 
advantage (achieved p = 0.11) of the new method of 
preventing new vascular events, although the frequency of 
these events in the apabetalone group was lower (9.5%) 
than expected (10.5%). Good tolerance of the new drug 
and few adverse effects during treatment encourage the 
continuation of studies concerning what Professor Kausik 
Ray from Imperial College London, Principal Investigator for 
this programme described as: “the first drug epigenetically 
modifying drug to be tested in cardsiovascular disease, with 
this very selective pathway; we remain optimistic”.
Leaving what we might call the ‘drugs of the future’ and 
going back to everyday clinical practice, it is worth noting 
the results of the TWILIGHT-ACS (Ticagrelor With AspIrin or 
ALone In HiGH-Risk Patients After Coronary InTervention for 
Acute Coronary Syndrome) programme, in which patients 
who underwent a percutaneous coronary intervention for 
reasons other than STEMI and completed a three-month-
-long double antiplatelet therapy were randomly assigned 
for 12 months to either a group treated using ticagrelor and 
acetylsalicylic acid or to a group treated using ticagrelor and 
a placebo [6]. During the 12-month observation, the group 
of patients treated via ticagrelor monotherapy exhibited — 
with a comparable frequency of vascular events — a 53% 
reduction in types 2, 3 and 5 haemorrhagic complications 
as per the classification adopted by the Bleeding Academic 
Research Consortium (except for fatal hemorrhage, this 
means any bleeding which requires a medical intervention, 
except for bleeding occurring within 48 hours of surgical 
revascularisation of the myocardium, which is classified 
as type 4, and bleeding where the patient does not seek 
medical attention — type 1), with no sign of reduced anti-
coagulation efficacy compared to double therapy. Professor 
Usman Baber from the Mount Synai Hospital in New York, 
who reported on the results of this trial, stressed that some 
patients are currently being deprived of double antiplatelet 
therapy for fear of severe bleeding, and the results of the 
TWILIGHT-ACS trial suggest that the new strategy — ticagre-
lor monotherapy following an acute coronary syndrome — 
reduces the risk of bleeding and simultaneously preserves 
the antiplatelet effect.
The AHA as an organisation not only aims to influen-
ce the education of specialists in the field of cardiology, 
but also to recognise the importance of raising public 
awareness with respect to the ability to affect risk factors 
for cardiovascular diseases. Hence the large-scale infor-
mation campaigns, which this year bore the slogan: “HEY 
BIG VAPE, #QUIT LYING”. This campaign aims to disrupt 
thinking about e-cigarettes as a harmless form of stimulant 
because of numerous reports on the clearly pathogenic role 
of e-cigarettes. It aims to involve legislators and agencies 
which regulate access to such products in a fight to limit 
young people’s access to e-cigarettes.
To conclude this selective overview of topics covered 
during the recent AHA sessions, a word about Polish accents 
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in Philadelphia 2019. Our country’s centres presented 24 re-
ports, either orally or via posters; the sessions were atten-
ded by selected Principal Investigators from the ISCHEMIA 
trial. Of note in the programme of Scientific Sessions is also 
a joint session of national cardiac societies, co-organised 
by the Polish Cardiac Society, entitled ‘Global Roundtable: 
Arrythmia in Unique Circumstances’. During this session, 
Tomasz Rechciński, MD, PhD, presented the case of a pa-
tient with Brugada syndrome and perspectives for molecular 
diagnostics with respect to this nosological unit.
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